Jennifer B. Dwyer, MD, PhD

JCP
BI 1358894 in Borderline Personality Disorder
Original Research

January 13, 2025

Although the primary endpoint was not met, BI 1358894 was well-tolerated with no increase in self-harm or suicidality.
, , , et al

Consensus Report on XT Use in Practice

Read the full report
Figure: Graphic promoting Consensus Report on Xanomeline-Trospium; colorful net design shown with JCP logo in lower left.

Subscribe to read
more articles

Subscribe